Topical Metformin Versus Topical Ketotifen in Melasma Treatment

Launched by ASSIUT UNIVERSITY · Apr 16, 2025

Keywords

ClinConnect Summary

This clinical trial is looking at two different treatments for melasma, a skin condition that causes dark patches on the face. The researchers want to compare a new version of topical metformin, which is made using tiny particles, to topical ketotifen, also made with tiny particles. They will test these treatments alone and in combination with a procedure called micro-needling, which involves using small needles to help improve the skin. The study will involve 102 women who have been diagnosed with bilateral melasma, meaning they have patches on both sides of their face.

To participate in this trial, women must be at least 18 years old and have a clinical diagnosis of melasma. However, pregnant or nursing women, those using hormonal birth control, or anyone who has had certain skin treatments in the last three months cannot join. Participants can expect to have their skin treated with either of the creams on one side of their face, while the other side receives the other treatment. It's important for potential participants to understand that they will need to be able to give informed consent and have realistic expectations about the outcomes of the treatments. This study is not yet recruiting, so there will be more information available soon for those interested in participating.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Female adults of 18 years and above with bilateral melasma .
• • Clinical diagnosis of melasma.
• • Mental capacity to give informed consent.
• Exclusion Criteria:
• • Pregnant or nursing women.
• • Current use of hormonal birth control medication or any hormonal therapy.
• • Current or previous treatment by depigmenting agents within 3 months
• • History of laser or MN to the face within 3 months of study enrollment.
• • Patients with poor wound healing, recurrent herpes simplex and current skin infection (facial warts, molluscum contagiosum) and history of hypertropic scar/keloids.
• • Photosensitivity.
• • Patients with unrealistic expectations.